5-(4-甲基哌嗪-1-磺酰基)-1H-吲哚-1-羧酸叔丁酯 | 519148-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-(4-甲基哌嗪-1-磺酰基)-1H-吲哚-1-羧酸叔丁酯
• 英文名称: tert-Butyl 5-((4-methylpiperazin-1-yl)sulfonyl)-1H-indole-1-carboxylate
• 英文别名: tert-butyl 5-(4-methylpiperazin-1-yl)sulfonylindole-1-carboxylate
• CAS: 519148-73-3
• 化学式: C₁₈H₂₅N₃O₄S
• 分子量: 379.48
• InChiKey: AZTUCDDBRHLQSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  80.2
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  5-(4-甲基哌嗪-1-磺酰基)-1H-吲哚-1-羧酸叔丁酯 在 四(三苯基膦)钯 、 叔丁基锂 、 sodium carbonate 、 三氟乙酸 、 lithium chloride 作用下， 以 二氯甲烷 为溶剂， 生成 Indolyl quinolinone deriv. 14
  参考文献：
  名称：

  Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors

  摘要：

  Modifications to the basic side-chain of early lead structures of the indolyl quinolinone class of KDR kinase inhibitors resulted in improved pharmacokinctic and ancillary profiles. Specifically, compounds bearing 5-amido- and 5-sulphonamido-indolyl substituents exhibited lower plasma clearance and weaker binding affinity for the I-Kr potassium channel hERG. (C) 2003 Elsevier Science Ltd. All rights reserved. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.007
• 作为产物：
  描述：

  (9ci)-2,3-二氢-1-(三氟乙酰基)-1H-吲哚 在 氯磺酸 、 4-二甲氨基吡啶 、 manganese(IV) oxide 、 sodium hydroxide 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 5-(4-甲基哌嗪-1-磺酰基)-1H-吲哚-1-羧酸叔丁酯
  参考文献：
  名称：

  Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors

  摘要：

  Modifications to the basic side-chain of early lead structures of the indolyl quinolinone class of KDR kinase inhibitors resulted in improved pharmacokinctic and ancillary profiles. Specifically, compounds bearing 5-amido- and 5-sulphonamido-indolyl substituents exhibited lower plasma clearance and weaker binding affinity for the I-Kr potassium channel hERG. (C) 2003 Elsevier Science Ltd. All rights reserved. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.007

文献信息

• Tyrosine kinase inhibitors
  申请人：——

  公开号：US20040220216A1

  公开（公告）日：2004-11-04

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调节酪氨酸激酶信号传导的化合物，包含这些化合物的组合物以及使用它们治疗哺乳动物中的酪氨酸激酶依赖性疾病和状况的方法，如血管生成、癌症、肿瘤生长、动脉硬化、年龄相关性黄斑变性、糖尿病性视网膜病变、炎症性疾病等。
• US7169788B2
  申请人：——

  公开号：US7169788B2

  公开（公告）日：2007-01-30
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINES KINASES
  申请人：MERCK & CO INC

  公开号：WO2003037252A2

  公开（公告）日：2003-05-08

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
• Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors
  作者：Mark E. Fraley、Kenneth L. Arrington、Carolyn A. Buser、Patrice A. Ciecko、Kathleen E. Coll、Christine Fernandes、George D. Hartman、William F. Hoffman、Joseph J. Lynch、Rosemary C. McFall、Keith Rickert、Romi Singh、Sheri Smith、Kenneth A. Thomas、Bradley K. Wong

  DOI：10.1016/j.bmcl.2003.11.007

  日期：2004.1

  Modifications to the basic side-chain of early lead structures of the indolyl quinolinone class of KDR kinase inhibitors resulted in improved pharmacokinctic and ancillary profiles. Specifically, compounds bearing 5-amido- and 5-sulphonamido-indolyl substituents exhibited lower plasma clearance and weaker binding affinity for the I-Kr potassium channel hERG. (C) 2003 Elsevier Science Ltd. All rights reserved. (C) 2003 Elsevier Ltd. All rights reserved.